Rentschler Biopharma SE, a global CDMO for biopharmaceuticals, has made progress at its U.S. site in Milford, MA transforming the facility into a state-of-the-art, multi-product site. Following the company’s largest expansion, the newest manufacturing line is fully operational, and the company has a growing number of client projects that are being successfully onboarded and delivered.

The newest production line at the Milford, MA site represents the largest expansion in Rentschler Biopharma’s 150-year+ history and highlights the U.S. as a cornerstone of the company’s commercial strategy. The production line became fully operational in 2024, adding 22,000 sq.-ft. of manufacturing cleanroom space to the existing Milford site, significantly expanding the company’s global cGMP capacity, and housing four 2,000 L single-use bioreactors.

The facility supports a broad range of therapeutics across multiple modalities and disease areas, including oncology, hematology, musculoskeletal, cardiovascular, and organ failure indications. Over the past two years, seven new products have been successfully introduced to the site, including programs in or post PPQ (Process Performance Qualification).

Uwe Buecheler, PhD, Interim CEO, said, “With our expanded U.S. footprint, we combine deep technical expertise, a proven track record of high‑quality execution, and the long‑term stability of our family‑owned company. The progress we are seeing in Milford is the result of years of purposeful investment and the dedication of an exceptional team. This site is an integral part of our global network, enabling seamless continuity from early development through commercial supply.”

Tom Roberts, President of Rentschler Biopharma Inc. and General Manager U.S., added, “Our Milford site has entered a new phase of growth. We are onboarding diverse client programs, advancing late‑stage projects, and supporting partners from across the world who trust us with their most critical molecules. What sets us apart is our hands‑on scientific expertise and the way our teams work side‑by‑side with clients to design tailored solutions that keep programs moving forward with speed and confidence.”